Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial.

@article{Hamuryudan1998ThalidomideIT,
  title={Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial.},
  author={Vedat Hamuryudan and Cem Mat and Sebahattin Saip and Yilmaz Ozyazgan and Aksel Siva and Sabri Yurdakul and K. Zwingenberger and Hasan Yazici},
  journal={Annals of internal medicine},
  year={1998},
  volume={128 6},
  pages={443-50}
}
The Behcet syndrome is a type of systemic vasculitis characterized by recurrent aphthous ulcers of the mouth and genitalia; various skin lesions; arthritis; and relapsing, sight-threatening panuveitis (Figure 1). Arteries and veins of all sizes, the central nervous system, and the gastrointestinal tract are involved, with serious consequences [1]. The course of the syndrome consists of exacerbations and remissions, and the severity generally diminishes with time. The syndrome occurs throughout… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 106 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Other forms of vasculitis and pseudovasculitis.

Bailliere's clinical rheumatology • 1997
View 1 Excerpt

Vasculitis in Behçet's disease.

International reviews of immunology • 1997
View 1 Excerpt

Behcet ' s syndrome . How should we treat it ?

H Yazici, S Yurdakul, V Hamuryudan
Clinical Immunotherapeutics • 1995

Behcet's syndrome. How should we treat it? Clinical Immunotherapeutics

H Yazici, S Yurdakul, V. Hamuryudan
1995
View 1 Excerpt

Similar Papers

Loading similar papers…